European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previo... ( PEGINTRON and REBETOL(R) will be th...)

HOME >> MEDICINE >> TECHNOLOGY

European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy

Date:9/24/2007

PEGINTRON and REBETOL(R) will be the only available hepatitis C therapy approved in the EU for a retreatment indication, upon European Commission

approval

KENILWORTH, N.J., Sept. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of combination therapy with PEGINTRON(TM) (peginterferon alfa-2b, 1.5 mcg/kg once weekly) and REBETOL(R) (ribavirin, 800 - 1,400 mg daily) for retreating adult patients with chronic hepatitis C whose previous treatment with interferon alpha (pegylated or non- pegylated) and ribavirin combination therapy or interferon alpha monotherapy did not result in a sustained response. Upon European Commission approval, PEGINTRON and REBETOL will be the only available hepatitis C therapy in the European Union (EU) indicated for retreatment of prior treatment failures.

"A large and growing number of patients whose previous hepatitis C therapy did not result in a sustained response are in need of viable treatment options today," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "Upon EU approval of this new indication, PEG-INTRON combination therapy will help address this serious unmet medical need."

The CHMP recommendation serves as the basis for a European Commission approval of this expanded indication for PEGINTRON and REBETOL combination therapy, which is currently approved in the European Union (EU) for treating chronic hepatitis C in naive (previously untreated) adult patients, including naive patie
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. Malvern initiates European user group meetings for chemical imaging
7. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
8. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Inspire Announces Presentations at Two European Scientific Conferences
11. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

Post Your Comments:

(Date:11/30/2009)... , NEW YORK, Nov. 30 Reportli...rt is available in its catalogue: ,, Outsourci...4) ,, http://www.reportlinker.com/p0165747/Ou... ,, Report Description ,, Medical devices ...ector with an estimated size of $250 billion in 20...

(Date:11/30/2009)... MT. LAUREL, N.J., Nov. 30 /PRNewswire-FirstCall...rovider of technology-enabled clinical documentati... at the Radiological Society of North America (RSN...r Radiology, the product leverages SpeechQ(TM), th...on application used by thousands of radiologists. ...

(Date:11/30/2009)..., COVINA, Calif., Nov. 30 StemCyt...ialization agreement with Academia Sinica, the Nat...y methods and Intellectual Property (IP) related t... This method and IP was pioneered by a team led b...mia Sinica. Professor Lin is currently the exclus...

[0] Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014)[0] MedQuist Features SpeechQ VTB for Radiology Solution at RSNA Convention [0] StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke

... Inc.,(Nasdaq: OREX ) today announced changes to...s on its late-stage obesity programs and realign i...se changes are as follows: , -- The explora...(zonisamide and olanzapine to mitigate antipsychot...e and naltrexone to reduce symptoms of obsessive-,...

...ublished in,EuroIntervention showed that the expec...r with the MitraClip(R) system to correct mitral r...y significant mitral stenosis. Additionally,with t...d with the,MitraClip(R) system required surgery fo...rences were reported between the use of one or two...

Other Medicine Technology:Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2 Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System

(Date:12/1/2009)... Amadeus will operate as a division of Xybion...lls, NJ (PRWEB) December 1, 2009 -- Xybion Corpora...uisition of all operating assets of Quebec City ba... of enterprise governance, risk, compliance and qu... a corporate performance management organization h...

(Date:12/1/2009)... Recent Reviews In Major Peer Review Journals...ising New Developments For The Evidence-Based Asse...iculties. Some Of The Most Recent Are Listed Below...009 -- Review written by: Leesa V. Huang Ph.D. for...No. 3 November 2009. A nice synopsis of this artic...

(Date:12/1/2009)... The Daniel Jordan Fiddle Foundation, a natio...p, advocate for, and support programs and services...isorders (ASD), has released a free informational ...zures: How To Recognize The Signs and Basic First... New York, NY (PRWEB) December 1, 2009 -- Statisti...

(Date:12/1/2009)...inn., Dec. 1 "The patient will see... for Blue Cross and Blue Shield of Minnesota,s 10,...he first Minnesotans - and the first in the contin...e(SM). Online Care Anywhere allows patients to acc...ng onto a computer or picking up the phone. Blue C...

(Date:12/1/2009)..., SHENZHEN, China, Dec. 1 /PRNewswire-Asia-Fi...SE: NPD ) ("Nepstar" or "the Company"), the larg...umber of directly operated stores,today announced...rter ended,September 30, 2009. ,, Financi...terminated a voting rights assignment agreement,w...

[0] Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions [0] Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV [0] Daniel Jordan Fiddle Foundation for Adults with Autism Offers Free Epilepsy First-Aid Brochure [0] Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM)[0] China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009

...estern University about the effects of epidural pa...at epidural analgesic given at the early stages of...n delivery. 728 pregnant ladies in their final ...s of labor tended to be in labor for less time and...

...d in traditional Indian medicine to treat diabetes...in a manner similar to prescription drugs. The ...salacia oblonga, which is native to regions of Ind..., the sugar that circulates throughout the body. I...

...ffect of diseases on contact with children it was ...s likely to get the kind of affection other kids r... HIV-positive parents report avoided certain types...en their own conditions. Researchers talked wit...

...dden emotional stress can result in severe but rev...c heart attack.// Stress cardiomyopathy is oft...According to the researchers, patients have actual...ypical heart attack including chest pain, fluid in...

...betes begins in Chennai today. The theme for the c...tions //and over 1000 doctors and researchers will...ld. The world congress for diabetes is held...three-day event that draws support from World Heal...

...dy researchers say the arthritis drug rofecoxib (V...k. For the study researchers looked at health reco...er had a heart attack when the research started. A...xicam, and the COX-2 inhibitor celecoxib (Celebrex...

Other Medicine News:

Epidural given in early labor may not lead to caesarian birth Herb Found To Be Effective In Controlling Blood Sugar Levels HIV-positive Parents Require More Counseling Sudden Stress Found To Mimic Heart Attack Symptoms Chennai Plays Hosts To The Diabetes World Congress Arthritis Drug – Rofecoxib , Found To Increase Heart Attack Ris

... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...

Medicine Products:

Felbamate Feces Culture, Routine Fecal pH Fecal Phenolphthalein

European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previo...( PEGINTRON and REBETOL(R) will be th...),Health